Free Trial

Verrica Pharmaceuticals (VRCA) FDA Events

Verrica Pharmaceuticals logo
$0.89 +0.07 (+8.42%)
As of 02:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
FDA Events for Verrica Pharmaceuticals (VRCA)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Verrica Pharmaceuticals (VRCA). Over the past two years, Verrica Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as VP-315 and YCANTH™. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Verrica Pharmaceuticals' Drugs in FDA Review

VP-315 - FDA Regulatory Timeline and Events

VP-315 is a drug developed by Verrica Pharmaceuticals for the following indication: For the Treatment of Basal Cell Carcinoma. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

YCANTH™ (cantharidin) - FDA Regulatory Timeline and Events

YCANTH™ (cantharidin) is a drug developed by Verrica Pharmaceuticals for the following indication: For molluscum contagiosum, which is primarily a pediatric disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Verrica Pharmaceuticals FDA Events - Frequently Asked Questions

However, the company does has had drugs under review or in active clinical development.

In the past two years, Verrica Pharmaceuticals (VRCA) has reported FDA regulatory activity for the following drugs: VP-315 and YCANTH™ (cantharidin).

The most recent FDA-related event for Verrica Pharmaceuticals occurred on April 7, 2025, involving YCANTH™ (cantharidin). The update was categorized as "Provided Update," with the company reporting: "errica Pharmaceuticals Inc provided a business update."

Current therapies from Verrica Pharmaceuticals in review with the FDA target conditions such as:

  • For the Treatment of Basal Cell Carcinoma - VP-315
  • For molluscum contagiosum, which is primarily a pediatric disease. - YCANTH™ (cantharidin)

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:VRCA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners